SavedAdd your journal

Journals / Journal of Kocaeli Health and Technology University / 2026 / Cilt: 4 Sayı: 1

The Indications and Effects of Ellagic Acid on Transmembrane Receptors in Cancer Types

Kanser Türlerinde Ellajik Asidin Transmembran Reseptörleri Üzerindeki Endikasyonları ve Etkileri

Soykan Agar(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0000-0002-9870-6882
Esra Acar(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0000-0002-0814-0820
Erfan Akhavan(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0009-0007-7475-391X
Erkan Gökoluk(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0009-0004-7372-7515
Ebru Öztürk(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0009-0001-5217-6230
Fadime Elmas Türkmen(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0009-0001-8120-1685
Ayşe Elbay(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0009-0004-0440-5141
Mahide Nur Mut(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0009-0005-0314-0046
İdil Ayça Furunci(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0009-0006-1970-2063
Ghassan Issa(KOCAELİ SAĞLIK VE TEKNOLOJİ ÜNİVERSİTESİ)0000-0002-0229-7632
Jane Bogdanov(Ss Cyril and Methodius University)0000-0003-1187-366X
Pages
103–127
Publication Date
2026-04-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall, the interactions of EA with various receptors in the development of various cancers suggest the potential of EA as a promising anticancer agent for the prevention of cancer and can be used for in silico and in vitro studies when its structure is derivatized.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Ellagic acid (EA), a naturally occurring polyphenolic compound found in fruits and medicinal plants, has gained considerable attention for its significant anticancer potential.
📊
Key Findings & Data:Recent studies have shown that EA demonstrates significant anticancer effects through the modulation of various transmembrane receptor-mediated signaling pathways controlling tumor development, angiogenesis, and metastasis.
💡
Conclusion & Impact:Overall, the interactions of EA with various receptors in the development of various cancers suggest the potential of EA as a promising anticancer agent for the prevention of cancer and can be used for in silico and in vitro studies when its structure is derivatized.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Ellajik Asit · Transmembran Reseptörler · Kolorektal Kanser

Abstract

Ellagic acid (EA), a naturally occurring polyphenolic compound found in fruits and medicinal plants, has gained considerable attention for its significant anticancer potential. Recent studies have shown that EA demonstrates significant anticancer effects through the modulation of various transmembrane receptor-mediated signaling pathways controlling tumor development, angiogenesis, and metastasis. This review paper summarizes the interactions of EA with the major receptors involved in the development of various cancers. The mechanisms of EA-induced anticancer effects include the inhibition of various receptors such as tyrosine kinases, vascular endothelial growth factor receptor 2 (VEGFR-2), epidermal growth factor receptor (EGFR), platelet-derived growth factor receptor (PDGFR), and insulin-like growth factor receptor (IGF-1R). These kinases regulate various oncogenic signaling pathways. EA inhibits the PI3K/AKT/mTOR, MAPK, and NF-κB signaling pathways, where it was shown to modulate hormone receptor signaling through estrogen receptors (ERα/ERβ) and androgen receptors. EA is also found to modulate various inflammatory receptor interactions through cytokine receptor pathways. These indications of EA with various receptors suppress the development of various cancers through the inhibition of angiogenesis, cancerous cell cycle progression, epithelial-mesenchymal transition, and metastasis, causing the apoptosis in cancerous cells. EA regulates the nuclear receptor pathway as well. These studies show that EA inhibits the development of various cancers of the gastrointestinal system, liver, pancreas, breast, prostate, lungs, bladder, and others. Overall, the interactions of EA with various receptors in the development of various cancers suggest the potential of EA as a promising anticancer agent for the prevention of cancer and can be used for in silico and in vitro studies when its structure is derivatized.

Özet

Ellajik asit (EA), meyvelerde ve tıbbi bitkilerde doğal olarak bulunan bir polifenolik bileşiktir ve önemli antikanser potansiyeli nedeniyle son yıllarda büyük ilgi görmüştür. Son çalışmalar, EA’nın tümör gelişimi, anjiyogenez (yeni damar oluşumu) ve metastazı kontrol eden çeşitli transmembran reseptör aracılı sinyal yolaklarını düzenleyerek güçlü antikanser etkiler gösterdiğini ortaya koymuştur. Bu derleme makalesi, farklı kanserlerin gelişiminde rol oynayan başlıca reseptörlerle EA’nın etkileşimlerini özetlemektedir. EA’nın oluşturduğu antikanser etkilerin mekanizmaları; tirozin kinazlar, VEGFR-2 (Vasküler Endotelyal Büyüme Faktörü Reseptörü-2), EGFR (Epidermal Büyüme Faktörü Reseptörü), PDGFR (Trombosit Kaynaklı Büyüme Faktörü Reseptörü) ve IGF-1R (İnsülin Benzeri Büyüme Faktörü Reseptörü) gibi çeşitli reseptörlerin inhibisyonunu içermektedir. Bu kinazlar birçok onkogenik sinyal yolağını düzenler. EA; PI3K/AKT/mTOR, MAPK ve NF-κB sinyal yollarını inhibe ederken, östrojen reseptörleri (ERα/ERβ) ve androjen reseptörleri aracılığıyla hormon reseptörü sinyalini de modüle ettiği gösterilmiştir. Ayrıca EA’nın, sitokin reseptör yolları üzerinden çeşitli inflamatuvar reseptör etkileşimlerini düzenlediği de bulunmuştur. EA’nın çeşitli reseptörlerle olan bu etkileşimleri; anjiyogenezi, kanserli hücre döngüsü ilerlemesini, epitel-mezenkimal geçişini ve metastazın inhibe edilmesi yoluyla çeşitli kanserlerin gelişimini baskılar ve kanserli hücrelerin apoptozuna sebep olur. EA aynı zamanda nükleer reseptör yollarını da düzenlemektedir. Bu çalışmalar, EA’nın gastrointestinal sistem, karaciğer, pankreas, meme, prostat, akciğer, mesane ve diğer birçok kanser türünün gelişimini inhibe edebildiğini göstermektedir. Genel olarak, EA’nın çeşitli reseptörlerle etkileşimleri, kanserin önlenmesi için umut verici bir antikanser ajan olabileceğini ve yapısı türevlendirildiğinde in silico ve in vitro çalışmalar için kullanılabileceğini ortaya koymaktadır.

🔖

Cite This Article

Agar, S., Acar, E., Akhavan, E., Gökoluk, E., Öztürk, E., Türkmen, F. E., Elbay, A., Mut, M. N., Furunci, İ. A., Issa, G., Bogdanov, J. (2026). The Indications and Effects of Ellagic Acid on Transmembrane Receptors in Cancer Types. Journal of Kocaeli Health and Technology University, Cilt: 4 Sayı: 1, 103–127. https://doi.org/10.66163/jokohtu.1910788

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (122)

  1. Saltoglu, G. T., Yalcın Azarkan, S., Sarıbas, G. S., & Yalcınkaya, S. (2026). Evaluation of anticancer effects of ellagic acid and cisplatin in cisplatin-sensitive and resistant breast cancer cells. Medical Oncology, 43, 162.
  2. Vanella, L., Di Giacomo, C., Acquaviva, R., Baragallo, I., Li Volti, G., Cardile, V., et al. (2013). Effects of ellagic acid on angiogenic factors in prostate cancer cells. Cancers (Basel), 5(2), 726–738.
  3. Golmohammadi, M., Zamanian, M. Y., Jalal, S. M., Noraldeen, S. A. M., Ramirez-Coronel, A. A., Oudaha, K. H., et al. (2023). A comprehensive review on ellagic acid in breast cancer treatment: From cellular effects to molecular mechanisms of action. Food Science & Nutrition, 11(11), 6715–6731.
  4. AbouAitah, K., Nassrallah, A., Soliman, A. A. F., Swiderska-Sroda, A., Chudoba, T., Smalc-Koziorowska, J., et al. (2025). Enhanced killing of colon cancer cells by mesoporous silica nanoparticles loaded with ellagic acid. Nanomaterials, 15, 1547.
  5. Wang, N., Wang, Z. Y., Mo, S. L., Loo, T. Y., Wang, D. M., Luo, H. B., et al. (2012). Ellagic acid, a phenolic compound, exerts anti-angiogenesis effects via the VEGFR-2 signaling pathway in breast cancer. Breast Cancer Research and Treatment, 134(3), 943-955.
  6. Noh, K. T., Cha, G. S., Kim, H. C., Lee, J. H., Ahn, S. C., Kim, D. K., & Park, Y. M. (2014). Ellagic acid modulates LPS-induced maturation of dendritic cells. Journal of Medicinal Food, 17(9), 996–1002.
  7. Kaisho, T., Takeuchi, O., Kawai, T., Hoshino, K., & Akira, S. (2001). Endotoxin-induced maturation of dendritic cells. Journal of Immunology, 166, 5688–5694.
  8. Arrighi, J. F., Rebsamen, M., Rousset, F., Kindler, V., & Hauser, C. (2001). Role for p38 MAPK in human dendritic cells. Journal of Immunology, 166, 3837–3845.
  9. Al-Harbi, S. A., Abdulrahman, A. O., Zamzami, M. A., & Khan, M. I. (2021). Urolithins in cancer prevention: A review. Frontiers in Nutrition, 8, 647582.
  10. Ceci, C., Lacal, P. M., Tentori, L., De Martino, M. G., Miano, R., & Graziani, G. (2018). Experimental evidence of the antimetastatic activity of ellagic acid. Nutrients, 10, 1756.
  11. Zhang, H. M., Zhao, L., Li, H., Xu, H., Chen, W. W., & Tao, L. (2014). Research progress on the anticarcinogenic actions and mechanisms of ellagic acid. Cancer Biology & Medicine, 11(2), 92-100.
  12. Pec´ina-Slaus, N. (2010). Wnt signal transduction pathway and apoptosis: a review. Cancer Cell International, 10, 22.
  13. Serra, R., Easter, S. L., Jiang, W., Baxley, S. E. (2011). Wnt5a as an effector of TGFβ in mammary development and cancer. Journal of Mammary Gland Biology and Neoplasia, 16, 157–167.
  14. Uraguchi, M., Morikawa, M., Shirakawa, M., Sanada, K., Imai, K., et al. (2004). Activation of WNT family expression and signaling in squamous cell carcinomas of the oral cavity. Journal of Dental Research, 83, 327–332.
  15. Barbolina, M. V., Burkhalter, R. J., Stack, M. S., et al. (2011). Diverse mechanisms for activation of Wnt signalling in the ovarian tumour microenvironment. Biochemical Journal, 437, 1–12.
  16. Najdi, R., Holcombe, R. F., & Waterman, M. L. (2011). Wnt signaling and colon carcinogenesis: Beyond APC. Journal of Carcinogenesis, 10, 5.
  17. Gaston-Massuet, C., Andoniadou, C. L., Signore, M., Jayakody, S. A., Charolidi, N., Kyeyune, R., et al. (2011). Increased wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans. Nutrition and Cancer, 63, 558–564.
  18. Bafico, A., Liu, G., Goldin, L., Harris, V., & Aaronson, S. A. (2004). An autocrine mechanism for constitutive Wnt pathway activation in human cancer cells. Cancer Cell, 6, 497–506.
  19. Anitha, P., Priyadarsini, R. V., Kavitha, K., Thiyagarajan, P., & Nagini, S. (2013). Ellagic acid coordinately attenuates Wnt/β-catenin and NF-κB signaling pathways to induce intrinsic apoptosis in an animal model of oral oncogenesis. European Journal of Nutrition, 52(1), 75–84.
  20. Endemann, G., Stanton, L. W., Madden, K. S., Bryant, C. M., White, R. T., & Protter, A. A. (1993). CD36 is a receptor for oxidized low-density lipoprotein. Journal of Biological Chemistry, 268, 11811–11816.
  21. Kunjathoor, V. V., Febbraio, M., Podrez, E. A., Moore, K. J., Andersson, L., Koehn, S., et al. (2002). Scavenger receptors class A-I/II and CD36 are the principal receptors responsible for the uptake of modified low-density lipoprotein, leading to lipid loading in macrophages. Journal of Biological Chemistry, 277, 49982–49988.
  22. Sudhesh Dev, S., Zainal Abidin, S. A., Farghadani, R., Othman, I., & Naidu, R. (2021). Receptor tyrosine kinases and their signaling pathways as therapeutic targets of curcumin in cancer. Frontiers in Pharmacology, 12, 772510.
  23. Kim, H., Banerjee, N., Ivanov, I., Pfent, C. M., Prudhomme, K. R., Bisson, W. H., et al. (2016). Comparison of anti-inflammatory mechanisms of mango (Mangifera indica L.) and pomegranate (Punica granatum L.) in a preclinical model of colitis. Molecular Nutrition & Food Research, 60(9), 1912–1923.
  24. Ding, Y., Wang, L., Song, J., & Zhou, S. (2017). Protective effects of ellagic acid against tetrachloride-induced cirrhosis in mice through the inhibition of reactive oxygen species formation and angiogenesis. Experimental and Therapeutic Medicine, 14: 3375-3380, 2017
  25. Umesalma, S., & Sudhandiran, G. (2010). Differential inhibitory effects of the polyphenol ellagic acid on inflammatory mediators NF-κB, iNOS, COX-2, TNF-α, and IL-6 in 1,2-dimethylhydrazine-induced rat colon carcinogenesis. Basic & Clinical Pharmacology & Toxicology, 107, 650–655.
  26. Lu, B., Moser, A. H., Shigenaga, J. K., Feingold, K. R., & Grunfeld, C. (2006). Type II nuclear hormone receptors, coactivator, and target gene repression in adipose tissue in the acute-phase response. Journal of Lipid Research, 47, 2179–2190.
  27. Gharavi, N., et al. (2007). Ellagic acid: A naturally occurring phenolic compound that inhibits the aryl hydrocarbon receptor-regulated expression of cytochrome P450 1A1. Life Sciences, 81(10), 786–795.
  28. Kujawska, M., et al. (2020). Potential of urolithin A in gastrointestinal protection. World Journal of Gastroenterology, 26(23), 3170–3181.
  29. Heber, D. (2008). Multitargeted therapy of cancer by ellagitannins. Cancer Letters, 269(2), 262–268.
  30. McCubrey, J. A., Steelman, L. S., Abrams, S. L., Lee, J. T., Chang, F., Bertrand, F. E., et al. (2006). Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Advances in Enzyme Regulation, 46(1), 249-279.
  31. Yousuf, M., Shamsi, A., Khan, P., Shahbaaz, M., AlAjmi, M. F., Hussain, A.,. & Hassan, M. I. (2020). Ellagic acid controls cell proliferation and induces apoptosis in breast cancer cells via inhibition of cyclin-dependent kinase 6. International Journal of Molecular Sciences, 21(10), 3526.
  32. Mandal, T., Shukla, D., Pattanayak, S., Barman, R., Ashraf, R., Dixit, A. K., et al. (2024). Ellagic acid induces DNA damage and apoptosis in cancer stem-like cells and overcomes cisplatin resistance. ACS Omega, 9(50), 48988-49000.
  33. Yashiro, M. (2014). Ulcerative colitis-associated colorectal cancer. World Journal of Gastroenterology, 20(44), 16389–16397.
  34. Zong, Y., Meng, J., Mao, T., Han, Q., Zhang, P., & Shi, L. (2023). Repairing the intestinal mucosal barrier of traditional Chinese medicine for ulcerative colitis: A review. Frontiers in Pharmacology, 14, 1273407.
  35. Kuo, W. T., Zuo, L., Odenwald, M. A., Madha, S., Singh, G., Gurniak, C. B., et al. (2021). The tight junction protein ZO-1 is dispensable for barrier function but critical for effective mucosal repair. Gastroenterology, 161(6), 1924–1939.
  36. Xiong, Y., Cheng, Z., Zhang, Y., Liu, T., Wan, Z., Xia, C., et al. (2025). Ellagic acid alleviates DSS-induced ulcerative colitis by inhibiting ROS/NLRP3 pathway activation and modulating gut microbiota in mice. European Journal of Nutrition, 64, 64.
  37. Wu, Y., Zhang, P., Fan, H., Zhang, C., Yu, P., Liang, X., et al. (2023). GPR35 acts a dual role and therapeutic target in inflammation. Frontiers in Immunology, 14, 1254446.
  38. Deng, H., Hu, H., Ling, S., Ferrie, A. M., & Fang, Y. (2012). Discovery of natural phenols as G protein-coupled receptor-35 (GPR35) agonists. ACS Medicinal Chemistry Letters, 3(2), 165–169.
  39. Xie, B., Wang, M., Xiao, Y., Zhang, X., Liu, M., Miao, J., et al. (2026). Tryptophan metabolic gatekeeping in epithelial repair: GPR35-KLF5 circuitry decodes mucosal damage signals for repair programming. Cell Death & Disease, 17, 25.
  40. Liu, H., Yang, L., Ma, X., Wang, G., Wang, D., Liu, X., et al. (2026). Identification of Ellagic Acid as a Natural GPR35 Agonist for Ulcerative Colitis Therapy. Biomolecules, 16(3), 434.
  41. Basu, S., Yang, J., Xu, B., Magiera-Mularz, K., Skalniak, L., Musielak, B., et al. (2019). Design, synthesis, evaluation, and structural studies of C2-symmetric small molecule inhibitors of programmed cell death-1/programmed death-ligand 1 protein-protein interaction. Journal of Medicinal Chemistry, 62, 7250–7263.
  42. Shin, E. J., Lee, J. S., Hong, S., Lim, T. G., & Byun, S. (2019). Quercetin directly targets JAK2 and PKCδ and prevents UV-induced photoaging in human skin. International Journal of Molecular Sciences, 20, 5262.
  43. Skalniak, L., Zak, K. M., Guzik, K., Magiera, K., Musielak, B., Pachota, M., et al. (2017). Small-molecule inhibitors of PD-1/PD-L1 immune checkpoint alleviate the PD-L1-induced exhaustion of T-cells. Oncotarget, 8, 72167–72181.
  44. Cheshomi, H., Bahrami, A. R., Rafatpanah, H., & Matin, M. M. (2022). The effects of ellagic acid and other pomegranate (Punica granatum L.) derivatives on human gastric cancer AGS cells. Human & Experimental Toxicology, 41, 09603271211064534.
  45. Mannino, F., Imbesi, C., Bitto, A., Minutoli, L., Squadrito, F., D’Angelo, T., et al. (2023). Anti-oxidant and anti-inflammatory effects of ellagic and punicic acid in an in vitro model of cardiac fibrosis. Biomedicine & Pharmacotherapy, 162, 114666.
  46. Tošović, J., & Bren, U. (2020). Antioxidative action of ellagic acid—A kinetic DFT study. Antioxidants, 9, 587.
  47. Bellini, M. F., Cadamuro, A. C. T., Succi, M., Proença, M. A., & Silva, A. E. (2012). Alterations of the TP53 gene in gastric and esophageal carcinogenesis. BioMed Research International, 2012, 891961.
  48. Senger, D. R., Van de Water, L., Brown, L. F., Nagy, J. A., Yeo, K. T., Yeo, T. K., et al. (1993). Vascular permeability factor (VPF, VEGF) in tumor biology. Cancer and Metastasis Reviews, 12, 303–324.
  49. Trott, O., & Olson, A. J. (2010). AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. Journal of Computational Chemistry, 31(2), 455–461.
  50. Liu, Z., Huang, H., Yu, Y., Li, L., Shi, X., & Wang, F. (2023). Exploring the mechanism of ellagic acid against gastric cancer based on bioinformatics analysis and network pharmacology. Journal of Cellular and Molecular Medicine, 27, 3878–3896.
  51. Tan, Z., Li, X., Chen, X., Wang, L., Chen, B., Ren, S., et al. (2024). Ellagic acid inhibits tumor growth in hepatocellular carcinoma. Heliyon, 10(1), e23931.
  52. Roberts, P. J., & Der, C. J. (2007). Targeting the Raf-MEK-ERK cascade in cancer. Oncogene, 26, 3291–3310.
  53. Garcia-Lezana, T., Lopez-Canovas, J. L., & Villanueva, A. (2021). Signaling pathways in hepatocellular carcinoma. Advances in Cancer Research, 149, 63–101.
  54. Li, W. W., Yu, J. Y., Xu, H. L., & Bao, J. K. (2011). Concanavalin A: A potential anti-neoplastic agent targeting apoptosis, autophagy and antiangiogenesis for cancer therapeutics. Biochemical and Biophysical Research Communications, 414, 282–286.
  55. Lee, J. H., Won, J. H., Choi, J. M., Cha, H. H., Jang, Y. J., Park, S., et al. (2014). Protective effect of ellagic acid on concanavalin A-induced hepatitis via toll-like receptor and mitogen-activated protein kinase/nuclear factor kappa B signaling pathways. Journal of Agricultural and Food Chemistry, 62, 10110–10117.
  56. Huang, H., Wang, J., Zhang, J., Cai, J., Pi, J., & Xu, J. F. (2021). Inspirations of cobalt oxide nanoparticle-based anticancer therapeutics. Pharmaceutics, 13(10), 159.
  57. Chattopadhyay, S., Dash, S. K., Tripathy, S., Das, B., Kar Mahapatra, S., Pramanik, P., et al. (2015). Cobalt oxide nanoparticles induced oxidative stress linked to activation of TNF-α/caspase-8/p38-MAPK signaling in human leukemia cells. Journal of Applied Toxicology, 35(6), 603–613.
  58. Losso, J. N., Bansode, R. R., Trappey, I. I., Bawadi, A., Truax, R., et al. (2004). In vitro anti-proliferative activities of ellagic acid. Journal of Nutritional Biochemistry, 15(11), 672–678.
  59. Chung, Y. C., Lu, L. C., Tsai, M. H., Chen, Y. J., Chen, Y. Y., Yao, S. P., et al. (2013). The inhibitory effect of ellagic Acid on cell growth of ovarian carcinoma cells. Evidence-based complementary and alternative medicine: eCAM, 2013, 306705.
  60. Mahmoudi, A., Zarrin Pour, V., & Salehzadeh, A. (2025). A novel cobalt oxide nanoparticle conjugated with ellagic acid arrests the cell cycle in the human liver cancer cell line. Scientific Reports, 15, 1797.
  61. Wojtunik-Kulesza, K., Niziński, P., Krajewska, A., Oniszczuk, T., Combrzyński, M., & Oniszczuk, A. (2025). Therapeutic potential of ellagic acid in liver diseases. Molecules, 30(12), 2596.
  62. Ahad, A., Ganai, A. A., Mujeeb, M., & Siddiqui, W. A. (2014). Ellagic acid, an NF-κB inhibitor, ameliorates renal function in experimental diabetic nephropathy. Chemico-Biological Interactions, 219, 64–75.
  63. Labrecque, L., Lamy, S., Chapus, A., Mihoubi, S., Durocher, Y., Cass, B., et al. (2005). Combined inhibition of PDGF and VEGF receptors by ellagic acid, a dietary-derived phenolic compound. Carcinogenesis, 26(5), 821–826.
  64. Wang, S., Cai, Y., Zhou, F., Zhang, M., Li, J., Shang, L., et al. (2025). Ellagic acid-mediated pyroptosis in hepatocellular carcinoma via the ESR1/G6PD pathway. Biochemical Pharmacology, 241, 11717.
  65. Jeon, Y., Yoo, J. E., Rhee, H., Kim, Y.-J., Kim, G. I., Chung, T., et al. (2015). YAP inactivation in estrogen receptor alpha-positive hepatocellular carcinoma with less aggressive behavior. Oncotarget, 6(33), 36311–36322.
  66. Sun, N., Zhong, X., Wang, S., Zeng, K., Sun, H., Sun, G., et al. (2020). ATXN7L3 positively regulates SMAD7 transcription in hepatocellular carcinoma with growth-inhibitory function. EBioMedicine, 62, 103108.
  67. Wu, H., Yao, S., Zhang, S., Wang, J.-R., Guo, P.-D., Li, X.-M., et al. (2017). Elevated expression of erbin destabilizes ERα protein and promotes tumorigenesis in hepatocellular carcinoma. Journal of Hepatology, 66(6), 1193–1204.
  68. Li, L., Li, Z., & Sacks, D. B. (2003). Calmodulin regulates the transcriptional activity of estrogen receptors. Journal of Biological Chemistry, 278(2), 1195–1200.
  69. Jaroszewicz, J., Januszkiewicz, M., Flisiak, R., Rogalska, M., Kalinowska, A., & Wierzbicka, I. (2008). Circulating vascular endothelial growth factor and its soluble receptors in patients with liver cirrhosis: Possible association with hepatic function impairment. Cytokine, 44, 14–17.
  70. Edderkaoui, M., Nair, V., Veeranki, S., Li, J., & Abbruzzese, J. L. (2008). Ellagic acid induces apoptosis in pancreatic cancer cells via NF-κB. World Journal of Gastroenterology, 14(23), 3672–3680.
  71. Kim, H. J., Moon, S. Y., Kim, J. S., Kim, Y. H., & Kim, S. H. (2017). Effect of ellagic acid on the proliferation in pancreatic cancer cells. Translational Cancer Research, 6(4), 710–719.
  72. Das, J., Singh, D., Patel, M., & Kumar, S. (2021). Formulation and in vitro evaluation of poly-(D, L-lactide-co-glycolide) (PLGA) nanoparticles of ellagic acid and its effect on human breast cancer MCF-7 cell line. International Journal of Current Pharmaceutical Research, 13(5), 56–62.
  73. Zhang, T., Li, Y., Wang, X., & Chen, J. (2014). Ellagic acid exerts anti-proliferation effects via modulation of TGF-β/Smad3 signaling in MCF-7 breast cancer cells. Asian Pacific Journal of Cancer Prevention, 15, 273–276.
  74. El-Sonbaty, S. M., Ibrahim, M. M., & Hassan, M. S. (2022). Antitumor and antibacterial efficacy of gallium nanoparticles coated by ellagic acid. Dose-Response, 20(1), 1–15.
  75. Yue, W., Santen, R. J., & Simpkins, J. W. (2010). Estrogen receptor gene regulation and breast carcinogenesis. Endocrine-Related Cancer, 17, 1–10.
  76. Badr-Eldin, S. M., Saad, A. S., & Elgindy, N. A. (2022). Optimized apamin-mediated nano-lipidic carrier potentially enhances the cytotoxicity of ellagic acid against human breast cancer cells. International Journal of Molecular Sciences, 23, 9440.
  77. Gupta, S., Kunta, M., & Davis, R. J. (2005). Role of NF-κB signaling pathway in increased TNF-induced apoptosis. Cell Death & Differentiation, 12, 177–183.
  78. Lu, G., Sun, Y., Wang, Z., Li, Y., & Chen, X. (2023). The multifaceted mechanisms of ellagic acid in the treatment of tumors: State-of-the-art. Biomedicine & Pharmacotherapy, 165, 115132.
  79. Zhao, M., Yang, X., & Wang, Y. (2013). Ellagic acid inhibits human pancreatic cancer growth and EMT progression. Cancer Letters, 337, 210–217.
  80. Harper, P. (2023). A review of the dietary intake, bioavailability and health benefits of ellagic acid with a primary focus on its anti-cancer properties. Cureus, 15(8), e43156.
  81. Wang, L. S., Stoner, G. D., & Singh, A. (2011). Modulation of biomarkers of colorectal cancer by black raspberries. Clinical Cancer Research, 17, 598–610.
  82. Yousuf, M., Wang, J., & Li, X. (2020). Ellagic acid controls cell proliferation and induces apoptosis in breast cancer cells via inhibition of cyclin-dependent kinase 6. International Journal of Molecular Sciences, 21, 3526.
  83. Hsu, J. L., Hung, M. C., & Chen, G. (2014). CDK6 and RB-E2F signaling in tumor development. Cell Cycle, 13, 5–12.
  84. Vanella, L., Di Giacomo, C., Acquaviva, R., Barbagallo, I., Cardile, V., Kim, D.H., Abraham, N.G., Sorrenti, V. (2013). Apoptotic markers in a prostate cancer cell line. Oncology Reports, 30(6), 2804-2810.
  85. Malik, A., Afaq, S., Shahid, M., Akhtar, K., Assiri, A. (2011). Influence of ellagic acid on prostate cancer proliferation. Asian Pacific Journal of Tropical Medicine. 4, 550-555.
  86. Cavarretta, I.T., Neuwirt, H., Untergasser, G., Moser, P.L., Zaki, M.H., Steiner, H., et al. (2005). Antiapoptotic effect of IL-6 in advanced prostate cancer. Cancer Research. 65:10476-10485.
  87. Heber, D. (2008). Multitargeted therapy of cancer by ellagitannins. Cancer Letters, 269(2), 262-268.
  88. Sartippour, M. R., Seeram, N. P., Rao, J. Y., Moro, A., Harris, D. M., Henning, S. M.,. & Heber, D. (2008). Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. International Journal of Oncology, 32(2), 475-480.
  89. Eskandari, E., Heidarian, E., Amini, S. A., & Saffari-Chaleshtori, J. (2016). Evaluating the effects of ellagic acid on pSTAT3, pAKT, and pERK1/2 signaling pathways in prostate cancer PC3 cells. Journal of Cancer Research and Therapeutics, 12(3), 1266-1271.
  90. Albrecht, M., Jiang, W., Kumi-Diaka, J., Lansky, E. P., Gommersall, L. M., Patel, A., et al. (2004). Pomegranate extracts potently suppress proliferation, xenograft growth, and invasion of human prostate cancer cells. Journal of Medicinal Food, 7(3), 274-283.
  91. Naiki-Ito, A., Chewonarin, T., Tang, M., Pitchakarn, P., Kuno, T., Ogawa, K., et al. (2015). Ellagic acid, a component of pomegranate fruit juice, suppresses androgen-dependent prostate carcinogenesis via induction of apoptosis. The Prostate, 75(2), 151–160.
  92. Eskra, J. N., Schlicht, M. J., & Bosland, M. C. (2019). Effects of black raspberries and their ellagic acid and anthocyanin constituents on taxane chemotherapy of castration-resistant prostate cancer cells. Scientific Reports, 9(1), 4367.
  93. Jacob, A., Raj, R., Allison, D. B., & Myint, Z. W. (2021). Androgen Receptor Signaling in Prostate Cancer and Therapeutic Strategies. Cancers, 13(21), 5417.
  94. Denmeade, S. R., Lin, X. S., & Isaacs, J. T. (1996). Role of programmed (apoptotic) cell death during the progression and therapy for prostate cancer. Prostate, 28, 251–265.
  95. Liang, Y. C., Tsai, S. H., Chen, L., Lin-Shiau, S. Y., & Lin, J. K. (2003). Resveratrol-induced G2 arrest through the inhibition of CDK7 and p34CDC2 kinases in colon carcinoma HT29 cells. Biochemical Pharmacology, 65, 1053–1060.
  96. Jeong, K. J., Cho, K. H., Panupinthu, N., Kim, H., Kang, J., Park, C. G., et al. (2013). EGFR mediates LPA-induced proteolytic enzyme expression and ovarian cancer invasion: Inhibition by resveratrol. Molecular Oncology, 7, 121–129.
  97. Vergara, D., Simeone, P., Toraldo, D., Del Boccio, P., Vergaro, V., Leporatti, S., et al. (2012). Resveratrol downregulates Akt/GSK and ERK signalling pathways in OVCAR-3 ovarian cancer cells. Molecular BioSystems, 8, 1078–1087.
  98. Ferry-Dumazet, H., Garnier, O., Mamany-Matsuda, M., Vercauteren, J., Belloc, F., Billiard, C., et al. (2002). Resveratrol inhibits the growth and induces the apoptosis of both normal and leukemic hematopoietic cells. Carcinogenesis, 23, 1327–1333.
  99. Dow, R. L., Chou, T. T., Bechle, B. M., Goddard, C., & Larson, E. R. (1994). Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine protein kinase inhibitors. Journal of Medicinal Chemistry, 37, 2224–2231.
  100. Al-Taweel, A. M., Perveen, S., Fawzy, G. A., Mehmood, R., Khan, A., & Khan, S. I. (2016). New ellagic acid derivative from Conocarpus lancifolius and their PPAR agonistic activities. Pakistan Journal of Pharmaceutical Sciences, 29(5 Suppl), 1833–1837.
  101. Saadullah, M., Chaudary, B. A., Uzair, M., & Afzal, K. (2014). Antidiabetic potential of Conocarpus lancifolius. Bangladesh Journal of Pharmacology, 9(2), 244–249.
  102. Yenerall, P., & Kittler, R. (2015). Harnessing the nuclear receptor PPARγ to inhibit the growth of lung adenocarcinoma by rewiring metabolic circuitries. Molecular & Cellular Oncology, 2(2), e980660.
  103. Kuete, V., Wiench, B., Alsaid, M. S., Alyahya, M. A., Fankam, A. G., Shahat, A. A., et al. (2012). Cytotoxicity and antimicrobial activities of Saudi plants. Phytochemistry Letters, 5, 425–430.
  104. Jeong, H., Phan, A. N. H., & Choi, J. W. (2017). Anti-cancer effects of polyphenols in EGFR-resistant lung cancer. Pharmacognosy Magazine, 13(52), 595–599.
  105. Amin, A. R., Küçük, O., Khuri, F. R., & Shin, D. M. (2009). Perspectives for cancer prevention with natural compounds. Journal of Clinical Oncology, 27(16), 2712–2725.
  106. Čižmáriková, M., Michalková, R., Mirossay, L., Mojžišová, G., Zigová, M., Bardelčíková, A., et al. (2023). Ellagic acid and cancer hallmarks: Insights from experimental evidence. Biomolecules, 13, 1653.
  107. Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.
  108. Subramaniam, S., Thakur, R. K., Yadav, V. K., Nanda, R., Chowdhury, S., & Agrawal, A. (2013). Lung cancer biomarkers: State of the art. Journal of Carcinogenesis, 12, 3.
  109. Herbst, R. S., Heymach, J. V., & Lippman, S. M. (2008). Lung cancer. New England Journal of Medicine, 359(13), 1367–1380.
  110. Lorenzon, E., Colladel, R., Andreuzzi, E., Marastoni, S., Todaro, F., Schiappacassi, M., et al. (2012). MULTIMERIN2 impairs tumor angiogenesis and growth by interfering with VEGF-A/VEGFR2 pathway. Oncogene, 31(26), 3136–3147.
  111. Crew, J. P., O’Brien, T., Bicknell, R., Fuggle, S., Cranston, D., & Harris, A. L. (1999). Urinary vascular endothelial growth factor and its correlation with bladder cancer recurrence rates. Journal of Urology, 161, 799–804.
  112. Xia, G., Kumar, S. R., Hawes, D., Cai, J., Hassanieh, L., Groshen, S., et al. (2006). Expression and significance of vascular endothelial growth factor receptor 2 in bladder cancer. Journal of Urology, 175, 1245–1252.
  113. Ceci, C., Tentori, L., Atzori, M. G., Lacal, P. M., Bonanno, E., Scimeca, M., et al. (2016). Ellagic acid inhibits bladder cancer invasiveness and in vivo tumor growth. Nutrients, 8(11), 744.
  114. Cetin, A., & Biltekin, B. (2020). Ellagic acid enhances antitumor efficacy in glioblastoma. Turkish Neurosurgery, 30(6), 813–821.
  115. Wang, D., Chen, Q., Liu, B., Li, Y., Tan, Y., & Yang, B. (2016). Ellagic acid inhibits proliferation in human glioblastoma cells. Acta Cirúrgica Brasileira, 31(2), 143–149.
  116. Wild-Bode, C., Weller, M., & Wick, W. (2001). Molecular determinants of glioma cell migration. Journal of Neurosurgery, 94, 978–984.
  117. Ma, R. J., Ma, C., Hu, K., Zhao, M. M., & Zhang, N. (2022). Molecular mechanism, regulation, and therapeutic targeting of the STAT3 signaling pathway in esophageal cancer. International Journal of Oncology, 61(3), 105.
  118. Li, L. W., Na, C., Tian, S. Y., Chen, J., Ma, R., & Gao, Y. (2018). Ellagic acid induces HeLa cell apoptosis via regulating STAT3 signaling. Experimental and Therapeutic Medicine, 16(1), 29–36.
  119. Zapolnik, P., & Pyrkosz, A. (2020). RNF6 as an oncogene and potential therapeutic target—a review. BioTech, 9(4), 22.
  120. Priyadarsini, R. V., Vinothini, G., Murugan, R. S., Manikandan, P., & Nagini, S. (2011). The flavonoid quercetin modulates the hallmark capabilities of hamster buccal pouch tumours. Nutrition and Cancer, 63, 218–226.
  121. Yousuf, M., Shamsi, A., Khan, P., Shahbaaz, M., AlAjmi, M. F., Hussain, A.,. & Hassan, M. I. (2020). Ellagic acid controls cell proliferation and induces apoptosis in breast cancer cells via inhibition of cyclin-dependent kinase 6. International Journal of Molecular Sciences, 21(10), 3526.
  122. Sartippour, M. R., Seeram, N. P., Rao, J. Y., Moro, A., Harris, D. M., Henning, S. M.,. & Heber, D. (2008). Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. International Journal of Oncology, 32(2), 475-480.